C90
Conditions
Interventions
Group 1: All Patients with multiple myeloma, 18 years of age and older admitted to one of the three transplant wards of the Department of Hematology/Oncology, University Medical Center, Freiburg, Germ
Sponsors
Universitätsklinikum Freiburg
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: All Patients with MM, and 18 years of age and older admitted to one of the three transplant wards of the Department of Hematology/Oncology, University Medical Center, Freiburg, Germany, for HD and ASCT will be screened for inclusion criteria and consecutively included in the study. The criteria for inclusion are that the patients are able to read, understand, and answer the PROVIVO questionnaire and that HD and ASCT is part of the first treatment regimen after diagnosis.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom experience of patients will be measured with the PROVIVO questionnaire at four timepoints: admission (day -4, calculated from day of ASCT), nadir (moment of lowest count of white blood cells, about day +7 to +10), discharge (about day +15) and one month after discharge of HD and ASCT (30 days after discharge). | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the PROVIVO questionnaire for the use with patients with multiple myeloma and HD and ASCT | — |
Countries
Germany
Contacts
Public ContactMatthias Naegele
Universitätsklinikum Freiburg
Outcome results
None listed